Merida Biosciences Acquisition, Valuation, Funding & Investors

BioArctic AB is a research-based biopharmaceutical company focusing on disease-modifying treatments and diagnostics for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, and ALS. Geographically, it derives a majority of its revenue from North America.

Precigen Inc is a biotechnology company that develops synthetic biology solutions. The company designs build and regulate gene programs. Its technologies are broadly applicable across a wide range of diverse end markets. Intrexon's business model is to commercialize its technologies through exclusive channel collaborations with collaborators that have specific industry expertise, development resources, and sales and marketing capabilities, in order to bring new and improved products and processes to market. Its reportable segments are Biopharmaceuticals and Exemplar. The company's collaborators provide compensation through technology access fees, royalties, milestones, and reimbursement of certain costs.

Betta Pharmaceuticals Co Ltd is a pharmaceutical enterprise that focuses on the research and development of innovative medicines. The company's drug is used for various diseases such as malignant tumors, diabetes, and cardio-cerebrovascular disease. Further, it offers Icotinib hydrochloride, an orally administered small-molecule and a reversible tyrosine kinase inhibitor, which is used for the treatment of non-small-cell lung cancer. Geographically, the group operates in China.

Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune systems.

Samchundang Pharm Co Ltd is engaged in manufacturing, distributing, importing, and exporting pharmaceuticals in South Korea. The company offers ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as gastro intestines and vitamins.

Kangmei Pharmaceutical Co Ltd is a pharmaceutical company engaged in the trading of Chinese herbal medicines, production and sales of Chinese herbal medicine slices, Chinese patent medicine preparations, health foods, chemical drugs, and medical devices, modern pharmaceutical logistics system. The company is also engaged in medical equipment, property leasing and sales, and other services.

Heyuan Biotechnology is a Chinese provider of gene therapy services, specializing in AAV and lentiviral vector production, CRISPR-based gene editing, and in vivo efficacy testing. Operating from facilities certified under ISO 13485, it supports pharma clients with plasmid design, viral packaging at titers exceeding 10^13 vg/mL, and animal model studies for CNS and oncology targets.

Virbac SA is a drug manufacturing company with a focus on animal health. The company generates the vast majority of its revenue in Europe, and it also has its presence in Europe, North America, Far East Asia, India, Africa & Middle East (IMEA), Pacific, and Latin America.

Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.

AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.

Xiamen Amoytop Biotech Co Ltd operates as a drug development company. The Company develops and sells protein drugs, interferon drugs, and other products.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Sunshine Lake Pharma Co Ltd is a a vertically integrated pharmaceutical company engaging in research and development, production and commercialization of pharmaceutical products. It strategically focus on therapeutic areas of infectious diseases, chronic diseases and oncology. Its existing anti-infective product portfolio mainly includes (i) its top-selling product, Kewei (oseltamivir phosphate), for the treatment of influenza (in particular, Type A and Type B influenza viruses), (ii) one innovative drug developed in-house, Dongweien (emitasvir phosphate), for the treatment of hepatitis C, and (iii) three generic drugs for the treatment of infections caused by sensitive bacteria, namely Clarithromycin, Levofloxacin and Moxifloxacin Hydrochloride.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.

NewLimit is a South San Francisco-headquartered biotechnology company advancing epigenetic reprogramming to extend human healthspan. The firm develops therapies restoring cellular function in aging tissues, targeting diseases like neurodegeneration and cardiovascular conditions. NewLimit's platform integrates machine learning with partial reprogramming techniques to identify optimal rejuvenation protocols.

Shiji Biotechnology is a Beijing-headquartered developer of genetic technologies for swine breeding. The company engineers pig breeds resistant to diseases like African swine fever using CRISPR gene editing. Shiji offers breeding stock, semen, and consulting services to large-scale farms across China. Established in 2016, it collaborates with the Chinese Academy of Agricultural Sciences on porcine genomics research.

Sail Biomedicines engineers precision medicines using circular RNA technology called Endless RNA combined with programmable nanoparticles. Cambridge, Massachusetts-headquartered and founded in 2022, the platform designs targeted therapies for oncology, infectious diseases, and genetic disorders. Sail's approach leverages natural lipid components for enhanced delivery and protein expression. The company collaborates with research institutions on preclinical candidates advancing toward clinical trials.